[ Bicycle Therapeutics raises $52M in Series B funding ]

Bicycle Therapeutics has raised $52 million in Series B funding.

Founded in 2009, Bicycle Therapeutics  is a biotechnology company based at the Babraham Research Campus in Cambridge, U.K. developing a novel technology for the creation of a new generation of biotherapeutics which combine the desirable features of small molecules and biopharmaceuticals.

The new  money will go into early-stage work on drugs like BT1718 — which targets Membrane Type 1 Matrix Metalloproteinase, or MT1- MTP, expressed on tumor cells. These drugs are supposed to drop a toxic payload right on target — a familiar concept that Bicycle has a fresh twist on.

Funding  Series B
Founded  2009
Country  UK
City  Cambridge, Cambridgeshire
Founder / CEO  Rolf H. Guenther
Deal Size  $52M
Investors  Atlas Venture
 Vertex Ventures
 Cambridge Innovation Capital plc
 Longwood Founders Fund
 Novartis Venture Fund
 SV Health Investors
 SR One
Previous Investors   Astellas Venture Management
 Atlas Venture
 SR One
 Novartis Venture Fund
 SV Health Investors